外科肿瘤学
乳腺癌
生物标志物
可解释性
医学
特征选择
肿瘤科
判别式
磁共振成像
机器学习
分类器(UML)
乳房磁振造影
聚类分析
医学影像学
成像生物标志物
人表皮生长因子受体2
曲妥珠单抗
可视化
个性化医疗
模式识别(心理学)
靶向治疗
数据挖掘
精密医学
医学物理学
生物信息学
降维
无线电技术
基因表达谱
乳房成像
生物标志物发现
临床试验
乳腺摄影术
人工智能
计算机科学
作者
Chinting Wong,Qi Yang,Yanting Liang,Zhitao Wei,Yi Dai,Zeyan Xu,Xiaobo Chen,Siyao Du,Chu Han,Changhong Liang,Lína Zhang,Zaiyi Liu,Ying Wang,Zhenwei Shi
标识
DOI:10.1186/s13058-025-02118-2
摘要
Accurate classification of Human epidermal growth factor receptor 2 (HER2) expression is crucial for guiding treatment in breast cancer, especially with emerging therapies like trastuzumab deruxtecan (T-DXd) for HER2-low patients. Current gold-standard methods relying on invasive biopsy and immunohistochemistry suffer from sampling bias and interobserver variability, highlighting the need for reliable non-invasive alternatives. We developed an artificial intelligence framework that integrates a pretrained foundation model with a task-specific classifier to predict HER2 expression categories (HER2-zero, HER2-low, HER2-positive) directly from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). The model was trained and validated using multicenter datasets. Model interpretability was assessed through feature visualization using t-SNE and UMAP dimensionality reduction techniques, complemented by SHAP analysis for post-hoc interpretation of critical predictive imaging features. The developed model demonstrated robust performance across datasets, achieving micro-average AUCs of 0.821 (95% CI 0.795–0.846) and 0.835 (95% CI 0.797–0.864), and macro-average AUCs of 0.833 (95% CI 0.818–0.847) and 0.857 (95% CI 0.837–0.872) in external validation. Subgroup analysis demonstrated strong discriminative power in distinguishing HER2 categories, particularly HER2-zero and HER2-low cases. Visualization techniques revealed distinct, biologically plausible clustering patterns corresponding to HER2 expression categories. This study presents a reproducible, non-invasive solution for comprehensive HER2 phenotyping using DCE-MRI, addressing fundamental limitations of biopsy-dependent assessment. Our approach enables accurate identification of HER2-low patients who may benefit from novel therapies like T-DXd. This framework represents a significant advancement in precision oncology, with potential to transform diagnostic workflows and guide targeted therapy selection in breast cancer care.
科研通智能强力驱动
Strongly Powered by AbleSci AI